Success for SNG 001 (Synairgen) in early Asthma trial

In a mid-stage study of 134 adults who caught a cold, SNG001 from Synairgen, was effective in the most difficult-to-treat patients, preventing asthma symptoms from getting worse during the first week of infection and treatment. There was also a 65 percent reduction in the number of patients who experienced asthma attacks during the treatment period compared with a group on placebo. SNG001 is a beta interferon treatment that works by targeting virus infections, which trigger 80 percent of asthma attacks.